Personalis, Inc. Hits New 52-Week High of $11.84, Up 763.64%

Personalis, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 11.84 on May 29, 2026. This achievement marks a remarkable increase from its 52-week low of USD 3.84, reflecting a substantial year-over-year performance of 763.64%. The company, with a market capitalization of USD 710 million, operates in a competitive industry that has seen notable advancements. Despite being loss-making, Personalis, Inc. has demonstrated resilience in its market position. The stock's performance stands in stark contrast to the S&P 500, which has recorded a gain of 28.21% over the same period. Key financial metrics indicate a challenging landscape, with a negative return on equity of -43.10% and a debt-to-equity ratio of -0.82. The company does not offer a dividend yield, and its price-to-book ratio stands at 4.14. As Personalis, Inc. continues to navigate the complexities of the biotechnology field, this new high underscores its dynamic presence in the market.